An award-winning poster from Dr Mireia Musquera Felip et al. (Hospital Clinic Barcelona, Spain) reported their experience with robot-assisted kidney transplantation (RAKT) after 3 years, involving 185 RAKTs from 8 European centres (ERUS-RAKT project), most of which were living donor transplantations. The operating times, ischaemia times, and anastomosis times were all reasonable (see Table). Although some vascular complications were reported in the beginning of the project, the learning curve accelerated and fewer complications were reported later. The authors claim that they provide good surgical and functional results, which are competitive to the open technique. However, it is unclear what the exact benefits to the patient are to justify this approach; for example, ideally less hernia or wound infection would be associated with the same functional outcome.
Table: Surgical characteristics of 185 robot-assisted kidney transplantations in ERUS-RAKT project
ERUS-RAKT, EAU Robotic Urology Section – Robot-Assisted Kidney Transplantation.
In another study, Dr Mark Sullivan et al. (Oxford University, United Kingdom) presented a study about renal transplantation for larger kidney tumours (6.2 cm on average). Of the 36 patients included (most presented with solitary kidneys), 34 of the tumours were highly complex. The positive surgical margin rate was 5.6%, Clavien-Dindo III-V complications were reported in 56%, and there was relatively high mortality at 5.6%. With a 60-month follow-up, there was an impressive cancer-free survival of 96%. Furthermore, 79% were recurrence-free, and 83% were dialysis-free. The authors concluded that in selected patients, this approach offers a chance for renal preservation without compromising cancer control; the surgery itself is however complex and potentially hazardous.
Posted on
Previous Article
« The Urodynamics for Prostate Surgery Trial Next Article
History of the consensus meeting »
« The Urodynamics for Prostate Surgery Trial Next Article
History of the consensus meeting »
Table of Contents: EAU 2019
Featured articles
Prostate Cancer
Barentsz Trial – Bi-parametric MRI versus multi-parametric MRI
Enzalutamide plus ADT improves outcomes for metastatic hormone-sensitive prostate cancer
Prostate cancer active surveillance: Better patient risk stratification and use of imaging
The role of pelvic lymph node dissection in prostate cancer: Extended vs standard
When to use imaging and imaging-guided therapies
Radioguided surgery is the future?
Bladder Cancer
Largest safety study of its kind with atezolizumab in metastatic bladder cancer
Bladder cancer risk and early detection
Consensus treatment pathway for patients with limited pelvic lymph node involvement in otherwise localised bladder cancer
FGFR3 gene mutation: Favourable prognostic impact in bladder cancer
Bladder cancer in young patients
Spanish study directly links surgical volume with mortality in bladder cancer patients undergoing cystectomy
Updated interim results of phase 2 trial of pembrolizumab for high-risk NMIBC unresponsive to BCG
Robot-assisted radical cystectomy or open radical cystectomy?
Renal Transplantation and Renal Cell Carcinoma
Andrology
Microdissection testicular sperm extraction (microTESE)
Male infertility/Premature ejaculation
Testosterone replacement therapy: Safe and maybe even protective
Focus on treatment of erectile dysfunction and Peyronie’s disease
Penile prosthesis implantation
Functional Urology
Decision aids are too difficult for patients
Lower Urinary Tract Symptoms
The Urodynamics for Prostate Surgery Trial
Minimally invasive surgical techniques must compete against pharmacotherapy in benign prostate hyperplasia (BPH)
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy